Literature DB >> 20188762

Creation and characterization of a cell-death reporter cell line for hepatitis C virus infection.

Zhilei Chen1, Rudo L Simeon, Karuppiah Chockalingam, Charles M Rice.   

Abstract

The present study describes the creation and characterization of a hepatoma cell line, n4mBid, that supports all stages of the hepatitis C virus (HCV) life cycle and strongly reports HCV infection by a cell-death phenotype. The n4mBid cell line is derived from the highly HCV-permissive Huh-7.5 hepatoma cell line and contains a modified Bid protein (mBid) that is cleaved and activated by the HCV serine protease NS3-4A. N4mBid exhibited a 10-20-fold difference in cell viability between the HCV-infected and mock-infected states, while the parental Huh-7.5 cells showed <2-fold difference under the same conditions. The pronounced difference in n4mBid cell viability between the HCV- and mock-infected states in a 96-well plate format points to its usefulness in cell survival-based high-throughput screens for anti-HCV molecules. The degree of cell death was found to be proportional to the intracellular load of HCV. HCV-low n4mBid cells, expressing an anti-HCV short hairpin RNA, showed a significant growth advantage over naïve cells and could be rapidly enriched after HCV infection, suggesting the possibility of using n4mBid cells for the cell survival-based selection of genetic anti-HCV factors.

Entities:  

Mesh:

Year:  2010        PMID: 20188762      PMCID: PMC2857706          DOI: 10.1016/j.antiviral.2010.02.321

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  25 in total

Review 1.  The machinery of programmed cell death.

Authors:  K C Zimmermann; C Bonzon; D R Green
Journal:  Pharmacol Ther       Date:  2001-10       Impact factor: 12.310

2.  Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors.

Authors:  A Sirven; E Ravet; P Charneau; V Zennou; L Coulombel; D Guétard; F Pflumio; A Dubart-Kupperschmitt
Journal:  Mol Ther       Date:  2001-04       Impact factor: 11.454

Review 3.  The Bcl2 family: regulators of the cellular life-or-death switch.

Authors:  Suzanne Cory; Jerry M Adams
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

Review 4.  Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome.

Authors:  H J Alter; L B Seeff
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

Review 5.  Epidemiology of hepatitis C: geographic differences and temporal trends.

Authors:  A Wasley; M J Alter
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

6.  Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells.

Authors:  Masanori Ikeda; MinKyung Yi; Kui Li; Stanley M Lemon
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Persistent and transient replication of full-length hepatitis C virus genomes in cell culture.

Authors:  Thomas Pietschmann; Volker Lohmann; Artur Kaul; Nicole Krieger; Gabriele Rinck; Gabriel Rutter; Dennis Strand; Ralf Bartenschlager
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

8.  Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication.

Authors:  Keril J Blight; Jane A McKeating; Charles M Rice
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

9.  Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs.

Authors:  Steven S Carroll; Joanne E Tomassini; Michele Bosserman; Krista Getty; Mark W Stahlhut; Anne B Eldrup; Balkrishen Bhat; Dawn Hall; Amy L Simcoe; Robert LaFemina; Carrie A Rutkowski; Bohdan Wolanski; Zhucheng Yang; Giovanni Migliaccio; Raffaele De Francesco; Lawrence C Kuo; Malcolm MacCoss; David B Olsen
Journal:  J Biol Chem       Date:  2003-01-27       Impact factor: 5.157

10.  Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees.

Authors:  Jens Bukh; Thomas Pietschmann; Volker Lohmann; Nicole Krieger; Kristina Faulk; Ronald E Engle; Sugantha Govindarajan; Max Shapiro; Marisa St Claire; Ralf Bartenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

View more
  5 in total

Review 1.  Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target.

Authors:  Kevin D Raney; Suresh D Sharma; Ibrahim M Moustafa; Craig E Cameron
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

Review 2.  Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.

Authors:  Ali Sabahi; Susan L Uprichard; William C Wimley; Srikanta Dash; Robert F Garry
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

Review 3.  New hepatitis C virus drug discovery strategies and model systems.

Authors:  Snawar Hussain; Naina Barretto; Susan L Uprichard
Journal:  Expert Opin Drug Discov       Date:  2012-08-04       Impact factor: 6.098

4.  A screen for genetic suppressor elements of hepatitis C virus identifies a supercharged protein inhibitor of viral replication.

Authors:  Rudo L Simeon; Zhilei Chen
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

5.  Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice.

Authors:  Richard J P Brown; Birthe Tegtmeyer; Julie Sheldon; Tanvi Khera; Daniel Todt; Gabrielle Vieyres; Romy Weller; Sebastian Joecks; Yudi Zhang; Svenja Sake; Dorothea Bankwitz; Kathrin Welsch; Corinne Ginkel; Michael Engelmann; Gisa Gerold; Eike Steinmann; Qinggong Yuan; Michael Ott; Florian W R Vondran; Thomas Krey; Luisa J Ströh; Csaba Miskey; Zoltán Ivics; Vanessa Herder; Wolfgang Baumgärtner; Chris Lauber; Michael Seifert; Alexander W Tarr; C Patrick McClure; Glenn Randall; Yasmine Baktash; Alexander Ploss; Viet Loan Dao Thi; Eleftherios Michailidis; Mohsan Saeed; Lieven Verhoye; Philip Meuleman; Natascha Goedecke; Dagmar Wirth; Charles M Rice; Thomas Pietschmann
Journal:  Sci Adv       Date:  2020-11-04       Impact factor: 14.136

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.